Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 41
- Registration Number
- NCT00311844
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1513
- Registration Number
- NCT00308347
MK0954A-264 Filter Study (0954A-264)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 274
- Registration Number
- NCT00307060
Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 421
- Registration Number
- NCT00289874
Obese Hypertension Study (0954-315)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 261
- Registration Number
- NCT00289887
Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1640
- Registration Number
- NCT00284856
Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 122
- Registration Number
- NCT00281320
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 196
- Registration Number
- NCT00276458
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 579
- Registration Number
- NCT00276484
The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 39
- Registration Number
- NCT00276016
© Copyright 2024. All Rights Reserved by MedPath